Strategic Collaboration Announced

Regeneron Pharmaceuticals Inc. has entered into a groundbreaking agreement with Fujifilm Diosynth Biotechnologies, aiming to bolster the production and supply of Regeneron's commercial biologic medicines. This collaboration, centered at Fujifilm's North Carolina campus, represents a total investment exceeding $3 billion over a ten-year period, inclusive of technology transfer costs.

Commitment to Quality and Growth

"Our partnership with Fujifilm is a testament to our shared commitment to maintaining the highest standards while scaling production capabilities," stated Daniel Van Plew, Regeneron's Executive Vice President. The companies are already underway with efforts to operationalize additional capacity at Fujifilm's biologics manufacturing facility in Holly Springs, North Carolina.

Expanding US Manufacturing Footprint

Beyond this collaboration, Regeneron highlighted its comprehensive investment strategy in production and infrastructure across New York and North Carolina, with projected expenditures surpassing $7 billion. This initiative underscores Regeneron's dedication to strengthening the US pharmaceutical manufacturing sector.